Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / KLK6

KLK6

Basics

Aliases:
This biomarker is also known as:
  • Zyme,
  • Klk7,
  • Serine protease 9,
  • PRSS9,
  • HK-6,
  • kallikrein-related peptidase 6,
  • Neurosin,
  • Bssp,
  • Protease M,
  • SP59,
  • KLK-6,
  • PRSS18,
  • Serine protease 18,
  • Kallikrein-6,

View in BioMuta

Description…

Serine protease M expressed on epithelial cell surface and released in ECM. Tumor cells treated with a neutralizing KLK6 antibody migrate less than control cells, suggesting a role in invasion and metastasis. Overexpressed in primary breast tumors but not expressed in metastatic tumors.

Attributes

QA State: Accepted
Type: Protein
Short Name:

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Three
QA State: Accepted

Overview

Amplification of a chromosome 19q region with the entire kallikrein family associated with ovarian cancer.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. KLK6 alone was not a strong predictor.

Supporting Study Data

The following studies/protocols provide evidence supporting KLK6 indications for the Ovary…

PLCO Ovarian Phase III Validation Study

The obvious appeal of a strategy for the early detection of ovarian cancer is based upon the tendency for the disease to present at advanced stages associated with poor survival. If the diagnosis could be largely shifted to stages I or II associated with survival close to 90%, then the overall mortality for this disease could be dramatically altered without any advances in therapy. While approaches to ovarian cancer screening might include pelvic examination or sonography, a vast amount of information exists on potential blood markers for the disease. The precision of sensitivity and specificity estimates will be greater for larger versus smaller study populations; but the effect produced by differences in the populations studied cannot as easily be predicted. Most of the studies relied on phase II validation (i.e. case vs. control differences); but case groups may differ by disease stage and histology that may affect overall estimates of sensitivity. Many studies have limited case specimens to those collected pre-operatively, but not all were explicit in this regard. Few studies have used pre-diagnostic sera months or years before diagnosis, so-called Phase III studies. Similarly, the nature of the control group will also affect specificity estimates. Inclusion of surgical controls that have benign gynecological conditions such as fibroids, endometriosis, or benign ovarian tumors may elevate marker levels and lower specificity. One strategy, besides combining markers, to improve the sensitivity and/or specificity would be to use marker history in the context of serial testing. Elevated but declining marker levels would indicate a transient condition associated with marker production. Elevated but stable levels might indicate chronic but benign conditions associated with marker production, while elevated and increasing levels are more likely indicative of cancer. Our hypothesis is that a panel of biomarkers will have better performance characteristics as a screening test for pre-clinical ovarian cancer than any single marker, and yield a longer lead time than CA125 alone.

View more about this study
Biomarker Characteristics Summary
Notes Sensitivity Specificity Prevalence NPV PPV Specific Assay Type
For all cases, using general population controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory. 22.0 95.0 N/A N/A N/A
For early stage (more than 12 months prior to diagnosis), using general population controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory. 28.0 95.0 N/A N/A N/A
For late stage (within 12 months of diagnosis), using general population controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory. 14.0 95.0 N/A N/A N/A
Decision Rule

PMID:21372037

Additional Study-Specific Protocols
Study-Specific Publications
Study-Specific Resources

No study-specific resources defined.

SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study

Phase II specimens from 160 ovarian cancer cases and 640 benign disease or general population controls were assembled from four Early Detection Research Network (EDRN) or Ovarian Cancer Specialized Program of Research Excellence (SPORE) sites and used to rank 51 biomarkers. Top markers in phase II specimens included CA125, HE4, transthyretin, CA15.3, and CA72.4 with sensitivity at 95% specificity ranging from 0.73 to 0.40.

View more about this study
Biomarker Characteristics Summary
Notes Sensitivity Specificity Prevalence NPV PPV Specific Assay Type
For all cases, using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory. 24.0 95.0 N/A N/A N/A
For early stage (more than 12 months prior to diagnosis), using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory. 28.0 95.0 N/A N/A N/A
For late stage (within 12 months of diagnosis), using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory. 18.0 95.0 N/A N/A N/A
For all cases, using general population controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory. 22.0 95.0 N/A N/A N/A
For early stage (more than 12 months prior to diagnosis), using general population controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory. 28.0 95.0 N/A N/A N/A
For late stage (within 12 months of diagnosis), using general population controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory. 14.0 95.0 N/A N/A N/A
Decision Rule

PMID:21372037

Additional Study-Specific Protocols
Study-Specific Publications
Study-Specific Resources

No study-specific resources defined.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

Organ-Specific Resources

No organ-specific resources defined.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html